Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
VMF
DRUG PRODUCT COMPOSITIONS
0
Weekly News Recap #Phispers
1. Act 064992
2. Act-064992
3. Act064992
4. Actelion-1
5. N-(5-(4-bromophenyl)-6-(2-(5-bromopyrimidin-2-yloxy)ethoxy)pyrimidin-4-yl)-n'-propylaminosulfonamide
6. Opsumit
1. 441798-33-0
2. Opsumit
3. Act-064992
4. Act 064992
5. N-[5-(4-bromophenyl)-6-[2-[(5-bromo-2-pyrimidinyl)oxy]ethoxy]-4-pyrimidinyl]-n'-propylsulfamide
6. Act064992
7. Z9k9y9wmvl
8. 5-(4-bromophenyl)-6-[2-(5-bromopyrimidin-2-yl)oxyethoxy]-n-(propylsulfamoyl)pyrimidin-4-amine
9. N-(5-(4-bromophenyl)-6-(2-((5-bromo-2-pyrimidinyl)oxy)ethoxy)-4-pyrimidinyl)-n'-propylsulfamide
10. Chebi:76607
11. Actelion-1
12. Macitentan [inn]
13. N-(5-(4-bromophenyl)-6-(2-((5-bromopyrimidin-2-yl)oxy)ethoxy)pyrimidin-4-yl)-n'-propylsulfamide
14. N-[5-(4-bromophenyl)-6-{2-[(5-bromopyrimidin-2-yl)oxy]ethoxy}pyrimidin-4-yl]-n'- Propylsulfamide
15. Macitentan [usan:inn]
16. Unii-z9k9y9wmvl
17. Macitentanum
18. Sulfamide, N-(5-(4-bromophenyl)-6-(2-((5-bromo-2-pyrimidinyl)oxy)ethoxy)-4-pyrimidinyl)-n'-propyl-
19. Sulfamide, N-[5-(4-bromophenyl)-6-[2-[(5-bromo-2-pyrimidinyl)oxy]ethoxy]-4-pyrimidinyl]-n'-propyl-
20. Macitentan- Bio-x
21. Opsumit (tn)
22. Macitentan [mi]
23. Macitentan [jan]
24. Macitentan (jan/usan)
25. Macitentan [usan]
26. Macitentan [vandf]
27. (non-labelled)macitentan-d7
28. Macitentan [who-dd]
29. Mls006011174
30. Gtpl7352
31. Schembl1445625
32. Chembl2103873
33. Macitentan [orange Book]
34. Dtxsid50196063
35. Ex-a544
36. Hms3653n06
37. Hms3747e09
38. Cas:441798-33-0;macitentan
39. Bcp05309
40. Bdbm50395626
41. Mfcd17167076
42. S8051
43. Zinc43202140
44. Akos024463406
45. Am81244
46. Ccg-270155
47. Cs-0686
48. Db08932
49. Sb14841
50. Macitentan (actelion-1,act-064992)
51. Ncgc00346456-01
52. Ncgc00346456-05
53. Ac-30102
54. As-74590
55. Bm162771
56. Hy-14184
57. N-(5-(4-bromophenyl)-6-(2-(5-bromopyrimidin-2-yloxy)ethoxy)pyrimidin-4-yl)-n'-propylaminosulfonamide
58. Smr004702943
59. Db-070519
60. Ft-0696675
61. Sw219473-1
62. Act 064992; Act-064992
63. D10135
64. Q6724151
65. {[5-(4-bromophenyl)-6-{2-[(5-bromopyrimidin-2-yl)oxy]ethoxy}pyrimidin-4-yl]sulfamoyl}(propyl)amine
66. N-(5-(4-bromophenyl)-6-(2-((5-bromopyrimidin-2-yl)oxi)ethoxy)pyrimidin-4-yl)-n'-propylsulfuric Diamide
67. N-[5-(4-bromophenyl)-6-[2-[(5-bromo-2-pyrimidinyl)-oxy]ethoxy]-4-pyrimidinyl]-n'-propylsulfamide
68. N-[5-(4-bromophenyl)-6-[2-[(5-bromo-2-pyrimidinyl)oxy]ethoxy]-4-pyrimidinyl]-n'-propyl-sulfamide
69. N-[5-(4-bromophenyl)-6-{2-[(5-bromopyrimidin-2-yl)oxy]ethoxy}pyrimidin-4-yl]-n'-propylsulfuric Diamide
Molecular Weight | 588.3 g/mol |
---|---|
Molecular Formula | C19H20Br2N6O4S |
XLogP3 | 3.7 |
Hydrogen Bond Donor Count | 2 |
Hydrogen Bond Acceptor Count | 10 |
Rotatable Bond Count | 11 |
Exact Mass | 587.96130 g/mol |
Monoisotopic Mass | 585.96335 g/mol |
Topological Polar Surface Area | 137 Ų |
Heavy Atom Count | 32 |
Formal Charge | 0 |
Complexity | 642 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
1 of 2 | |
---|---|
Drug Name | Opsumit |
PubMed Health | Macitentan (By mouth) |
Drug Classes | Antihypertensive |
Drug Label | OPSUMIT (macitentan) is an endothelin receptor antagonist. The chemical name of macitentan is N-[5-(4-Bromophenyl)-6-[2-[(5-bromo-2-pyrimidinyl)oxy]ethoxy]-4-pyrimidinyl]-N'-propylsulfamide. It has a molecular formula of C19H20Br2N6O4S and a molecula |
Active Ingredient | Macitentan |
Dosage Form | Tablet |
Route | Oral |
Strength | 10mg |
Market Status | Prescription |
Company | Actelion Pharms |
2 of 2 | |
---|---|
Drug Name | Opsumit |
PubMed Health | Macitentan (By mouth) |
Drug Classes | Antihypertensive |
Drug Label | OPSUMIT (macitentan) is an endothelin receptor antagonist. The chemical name of macitentan is N-[5-(4-Bromophenyl)-6-[2-[(5-bromo-2-pyrimidinyl)oxy]ethoxy]-4-pyrimidinyl]-N'-propylsulfamide. It has a molecular formula of C19H20Br2N6O4S and a molecula |
Active Ingredient | Macitentan |
Dosage Form | Tablet |
Route | Oral |
Strength | 10mg |
Market Status | Prescription |
Company | Actelion Pharms |
Investigated for use/treatment in cardiovascular disorders, hypertension, and pulmonary hypertension.
Macitentan is indicated for the treatment of WHO group 1 pulmonary arterial hypertension (PAH) both alone and in combination with tadalafil.
FDA Label
Opsumit, as monotherapy or in combination, is indicated for the long-term treatment of pulmonary arterial hypertension (PAH) in adult patients of WHO Functional Class (FC) II to III.
Efficacy has been shown in a PAH population including idiopathic and heritable PAH, PAH associated with connective tissue disorders, and PAH associated with corrected simple congenital heart disease.
Treatment of chronic thromboembolic pulmonary hypertension (CTEPH)
Treatment of idiopathic pulmonary fibrosis, Treatment of pulmonary arterial hypertension, Treatment of systemic sclerosis
Treatment of functional single ventricle heart disease with total cavo-pulmonary connection
Macitentan acts primarily by reducing vasoconstriction and cell proliferation due to endothelin overexpression.
Endothelin A Receptor Antagonists
Compounds and drugs that bind to and inhibit or block the activation of ENDOTHELIN A RECECPTORS. (See all compounds classified as Endothelin A Receptor Antagonists.)
Endothelin B Receptor Antagonists
Compounds and drugs that bind to and inhibit or block the activation of ENDOTHELIN B RECEPTORS. (See all compounds classified as Endothelin B Receptor Antagonists.)
C02KX04
C02KX04
S76 | LUXPHARMA | Pharmaceuticals Marketed in Luxembourg | Pharmaceuticals marketed in Luxembourg, as published by d'Gesondheetskeess (CNS, la caisse nationale de sante, www.cns.lu), mapped by name to structures using CompTox by R. Singh et al. (in prep.). List downloaded from https://cns.public.lu/en/legislations/textes-coordonnes/liste-med-comm.html. Dataset DOI:10.5281/zenodo.4587355
C - Cardiovascular system
C02 - Antihypertensives
C02K - Other antihypertensives
C02KX - Antihypertensives for pulmonary arterial hypertension
C02KX04 - Macitentan
Absorption
Macitentan has a median Tmax of 8h although some studies have found up to 30h at higher doses. Although the bioavailability has not been experimentally determined, pharmacokinetic modeling has estimated it at 74%. Food has not been found to have a significant effect on absorption.
Route of Elimination
Eliminated 50% through urine and 24% through feces. Of the 50% excreted through the urine, none of the recovered dose was in the form of the parent drug nor the active metabolite.
Volume of Distribution
Macitentan has an apparent volume of distribution of 40-50L.
Clearance
Clearance data was not found.
Macitentan undergoes oxidative depropylation of the sulfonamide moiety via CYP3A4, 2C8, 2C9, and 2C19 to form the active metabolite M6. The ethylene glycol moiety undergoes oxidative cleavage via CYP2C9 to the alcohol metabolite M4. M4 is oxidized to its corresponding acid, M5, then hydrolyzed to the metabolite termed m/z 324. Oxidative depropylation of a distal carbon atom via CYP2C8, 2C9, and 2C19 forms M7. Hydrolysis of both macitentan and M5 produces M3. Finally M5 may be further metabolized via hydrolysis and hydroxylation to M2 or via glucuronidation to a glucuronide metabolite, M1.
The half-life of elimination of macitentan is 16 hours. The half-life of elimination of the active metabolite is 40-66h
Through complete blockade of tissular endothelin, Actelion-1 is expected to protect tissue from the damaging effect of elevated endothelin, specifically in the cardiovascular system. In pre-clinical studies, Actelion-1 also exhibited effects suggesting that it maintains the integrity of the vascular wall and improves long-term outcome. Accordingly, Actelion-1 may provide therapeutic benefit in a wide range of cardiovascular indications.
Macitentan is an antagonist which binds to the endothelin A and B receptors (EA and EB) and blocks signaling from endothelin-1 and -2. Pulmonary arterial hypertension has many different mechanisms which contribute to the development of endothelial dysfunction including elevated cytosolic calcium, genetic factors, epigenetic changes, and mitochondrial dysfunction. The focus of macitentan's mechanism relates to the role of overexpressed endothelin from the vascular endothelium. Endothelins are released in both a constitutive fashion from secretory vesicles and in response to stimuli via Weibel-Palade storage granules. Endothelins bind to the EA and EB receptors, with endothelins -1 and -2 having more affinity than endothelin-3. Binding to the Gq coupled EA receptor triggers Ca2+ release from the sarcoplasmic reticulum of smooth muscle cells via the phospholipase C (PLC) pathway. Downstream protein kinase C activation may also contribute to increased Ca2+ sensitivity of the contractile apparatus. EA receptor activation is also known to contribute to pulmonary artery smooth muscle cell proliferation. The binding of endothelins to the EB receptors acts in opposition to EA signaling by activating the same PLC cascade in endothelial cells to activate endothelial nitric oxide synthase. The subsequent release of nitric oxide produces vasodilation through the cyclic guanosine monophosphate cascade. Despite the greater presence of EB receptors on endothelial cells, they are still present on smooth muscle cells and may contribute to cell proliferation through the same mechanisms as EA receptors. Macitentan is thought to provide its therapeutic effect primarily via blocking signaling through EA which produces both decreased vasoconstriction via reduced smooth muscle cell contractility and attenuation of the hyperproliferation of smooth muscle cells found in PAH. Blockade of EB is less likely to contribute to a therapeutic effect as this signaling is responsible for the counter-regulatory vasodilatory signal.
Honour is a leading global CDMO and specialty chemicals manufacturer with seven world-class sites delivering quality-driven solutions.
GDUFA
DMF Review : Reviewed
Rev. Date : 2017-02-27
Pay. Date : 2016-12-28
DMF Number : 31213
Submission : 2017-01-05
Status : Active
Type : II
NDC Package Code : 69037-0030
Start Marketing Date : 2013-10-18
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
Available Reg Filing : ASMF |
LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.
TAPI, a leading global supplier of APIs, provides over 350 products and customized CDMO solutions for every stage of development.
GDUFA
DMF Review : Reviewed
Rev. Date : 2017-05-03
Pay. Date : 2017-02-22
DMF Number : 31416
Submission : 2017-04-13
Status : Active
Type : II
GDUFA
DMF Review : Reviewed
Rev. Date : 2017-01-04
Pay. Date : 2016-09-27
DMF Number : 30969
Submission : 2016-09-30
Status : Active
Type : II
NDC Package Code : 65015-872
Start Marketing Date : 2017-10-09
End Marketing Date : 2026-12-01
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 41444
Submission : 2025-03-28
Status : Active
Type : II
GDUFA
DMF Review : Reviewed
Rev. Date : 2017-06-22
Pay. Date : 2017-06-05
DMF Number : 31658
Submission : 2017-05-31
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 39273
Submission : 2023-12-12
Status : Active
Type : II
GDUFA
DMF Review : Reviewed
Rev. Date : 2017-01-24
Pay. Date : 2016-12-05
DMF Number : 31179
Submission : 2016-12-13
Status : Active
Type : II
Honour is a leading global CDMO and specialty chemicals manufacturer with seven world-class sites delivering quality-driven solutions.
GDUFA
DMF Review : Complete
Rev. Date : 2017-02-27
Pay. Date : 2016-12-28
DMF Number : 31213
Submission : 2017-01-05
Status : Active
Type : II
TAPI, a leading global supplier of APIs, provides over 350 products and customized CDMO solutions for every stage of development.
GDUFA
DMF Review : Complete
Rev. Date : 2017-05-03
Pay. Date : 2017-02-22
DMF Number : 31416
Submission : 2017-04-13
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2017-07-05
Pay. Date : 2017-04-17
DMF Number : 31664
Submission : 2017-04-28
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2017-06-01
Pay. Date : 2017-05-12
DMF Number : 31749
Submission : 2017-05-15
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2017-10-12
Pay. Date : 2017-08-30
DMF Number : 31957
Submission : 2017-09-15
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2016-12-22
Pay. Date : 2016-09-29
DMF Number : 30212
Submission : 2016-01-30
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2017-01-24
Pay. Date : 2016-12-05
DMF Number : 31179
Submission : 2016-12-13
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2017-06-22
Pay. Date : 2017-06-05
DMF Number : 31658
Submission : 2017-05-31
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2017-01-04
Pay. Date : 2016-09-27
DMF Number : 30969
Submission : 2016-09-30
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 39273
Submission : 2023-12-12
Status : Active
Type : II
Date of Issue : 2022-06-17
Valid Till : 2025-02-07
Written Confirmation Number : WC-0082
Address of the Firm : Karakhadi Plot No. 842-843, At - Karakhdi, Tal. - Padra, Dist - Vadodara 391 450...
Date of Issue : 2022-06-07
Valid Till : 2025-06-25
Written Confirmation Number : WC-0023
Address of the Firm : Survey no. 52,53,58,59,61 to 78,127&128, Pydibhimanvaram Village &Sy.No. 1,2,4t0...
Date of Issue : 2022-08-08
Valid Till : 2025-08-08
Written Confirmation Number : WC-0383
Address of the Firm : Unit-ll, Sy No * Parts of 454,455,457,458 & 459 Chandampet-Village, Shankarampet...
Registrant Name : Korea Janssen Co., Ltd.
Registration Date : 2014-06-23
Registration Number : Su4722-4-ND
Manufacturer Name : Lonza AG@[Manufacturer of Mi...
Manufacturer Address : Lonzastrasse, 3930 Visp, Switzerland@Via Sottobisio 42 A, 6828 Balerna, Switzerland@V...
Honour is a leading global CDMO and specialty chemicals manufacturer with seven world-class sites delivering quality-driven solutions.
NDC Package Code : 69037-0030
Start Marketing Date : 2013-10-18
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 59651-122
Start Marketing Date : 2024-01-05
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (50kg/50kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 49187-0822
Start Marketing Date : 2013-10-18
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 49187-0823
Start Marketing Date : 2013-10-18
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : DRUG FOR FURTHER PROCESSING
NDC Package Code : 69766-006
Start Marketing Date : 2016-02-01
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 65015-872
Start Marketing Date : 2017-10-09
End Marketing Date : 2026-12-01
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 82245-0117
Start Marketing Date : 2013-10-18
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 76397-014
Start Marketing Date : 2020-01-01
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1g/g)
Marketing Category : BULK INGREDIENT FOR HUMAN P...
NDC Package Code : 11722-058
Start Marketing Date : 2015-07-14
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (100kg/100kg)
Marketing Category : BULK INGREDIENT
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
NDC Package Code : 76397-044
Start Marketing Date : 2025-04-27
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Honour is a leading global CDMO and specialty chemicals manufacturer with seven world-class sites delivering quality-driven solutions.
About the Company : Honour is a leading global CDMO and a trusted manufacturer of specialty chemicals and ingredients. With seven world-class facilities built to meet global safety and quality standar...
LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
About the Company : LGM Pharma is a global leader in sourcing hard-to-find APIs and intermediates for the pharmaceutical and biotech industries. LGM is also a full service CDMO providing formulation, ...
Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.
About the Company : Established in 2004, Metrochem API is one of the fastest-growing APIs, pellets & intermediates manufacturers. It has 6 dedicated manufacturing facilities for its 3 core product gro...
About the Company : HRV Global is a leading global manufacturer, seller & exporter of a wide range of APIs, advanced intermediates, pellets, food grade chemicals, food additives & food ingredients. It...
TAPI, a leading global supplier of APIs, provides over 350 products and customized CDMO solutions for every stage of development.
About the Company : Founded in 1935, TAPI Technology & API Services has a long-standing tradition of advancing health through innovation and dedication. Today, we proudly build upon this legacy, drivi...
About the Company : Guangzhou Tosun Pharmaceutical was founded in 1999, which mainly focuses on importation & exportation of Active Pharmaceutical Ingrediants, Chemical Raw Materials, Intermediate, Ex...
About the Company : Laurus Labs is a leading research and development-driven pharmaceutical company in India. The company has grown consistently to become one of the leading manufacturers of Active Ph...
About the Company : Morepen Laboratories Ltd.’ is 31 years old company. Went to public in 1993. Manufacturer and Exporter of complex and high margins molecules (APIs/Intermediates) for regulated mar...
About the Company : Shanvr Life Sciences Pvt Ltd is a pharmaceutical product development company with a strong emphasis on research. Our approach centers around the creation of specialized generic, on...
About the Company : Teva was established in 1901. Our global headquarters are based in Israel. Today we have a portfolio of more than 3,500 medicines, and produce approximately 120 billion tablets and...
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Details:
Yuvanci (macitentan, tadalafil) is an FDC available as a film coated tablet, for the treatment of pulmonary arterial hypertension in adults, works by inhibiting endothelin receptor & PDE5 inhibitor.
Lead Product(s): Macitentan,Tadalafil
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Opsynvi
Study Phase: Approved FDFProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable September 30, 2024
Lead Product(s) : Macitentan,Tadalafil
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
European Commission Approves Yuvanci® for Patients with Pulmonary Arterial Hypertension
Details : Yuvanci (macitentan, tadalafil) is an FDC available as a film coated tablet, for the treatment of pulmonary arterial hypertension in adults, works by inhibiting endothelin receptor & PDE5 inhibitor.
Product Name : Opsynvi
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 30, 2024
Details:
Yuvanci (macitentan) is a ETA/ETB inhibitor small molecule drug candidate, which is indicated in combination with tadalafil for the treatment of pulmonary arterial hypertension in adult.
Lead Product(s): Macitentan,Tadalafil
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Yuvanci
Study Phase: Approved FDFProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable September 30, 2024
Lead Product(s) : Macitentan,Tadalafil
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
EU Approves Yuvanci for Pulmonary Arterial Hypertension Treatment
Details : Yuvanci (macitentan) is a ETA/ETB inhibitor small molecule drug candidate, which is indicated in combination with tadalafil for the treatment of pulmonary arterial hypertension in adult.
Product Name : Yuvanci
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 30, 2024
Details:
Yuvanci (macitentan, tadalafil) is an FDC available as a film coated tablet, for the treatment of pulmonary arterial hypertension in adults, works by inhibiting endothelin receptor & PDE5 inhibitor.
Lead Product(s): Macitentan,Tadalafil
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: ACT-064992D
Study Phase: Approved FDFProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable July 26, 2024
Lead Product(s) : Macitentan,Tadalafil
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
J&J Receives Positive CHMP Opinion for Yuvanci® in Pulmonary Arterial Hypertension
Details : Yuvanci (macitentan, tadalafil) is an FDC available as a film coated tablet, for the treatment of pulmonary arterial hypertension in adults, works by inhibiting endothelin receptor & PDE5 inhibitor.
Product Name : ACT-064992D
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 26, 2024
Details:
Opsynvi is a combination of macitentan (an endothelin receptor antagonist) and tadalafil (a phosphodiesterase 5 inhibitor), approved for adults with pulmonary arterial hypertension.
Lead Product(s): Macitentan,Tadalafil
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Opsynvi
Study Phase: Approved FDFProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 22, 2024
Lead Product(s) : Macitentan,Tadalafil
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
FDA Approves OPSYNVI® As First Once-Daily Combination Therapy for PAH
Details : Opsynvi is a combination of macitentan (an endothelin receptor antagonist) and tadalafil (a phosphodiesterase 5 inhibitor), approved for adults with pulmonary arterial hypertension.
Product Name : Opsynvi
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 22, 2024
Details:
ACT-064992D (macitentan/tadalafil ) Tablet act Endothelin A receptor antagonists, macitentan, and the PDE5 inhibitor, tadalafil, used for long-term treatment of PAH in adult patients of WHO Functional Class (FC) II to III.
Lead Product(s): Macitentan,Tadalafil
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: ACT-064992D
Study Phase: Phase IIIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable June 26, 2023
Lead Product(s) : Macitentan,Tadalafil
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : ACT-064992D (macitentan/tadalafil ) Tablet act Endothelin A receptor antagonists, macitentan, and the PDE5 inhibitor, tadalafil, used for long-term treatment of PAH in adult patients of WHO Functional Class (FC) II to III.
Product Name : ACT-064992D
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 26, 2023
Details:
A combination of opsumit (macitentan) and tadalafil is being investigated to improve pulmonary hemodynamics, where opsumit is an ERA antagonist and tadalafil relaxes blood vessels and lowers the blood pressure in lungs, to allow blood to flow more easily.
Lead Product(s): Macitentan,Tadalafil
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Opsynvi
Study Phase: Phase IIIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable June 03, 2023
Lead Product(s) : Macitentan,Tadalafil
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : A combination of opsumit (macitentan) and tadalafil is being investigated to improve pulmonary hemodynamics, where opsumit is an ERA antagonist and tadalafil relaxes blood vessels and lowers the blood pressure in lungs, to allow blood to flow more easily...
Product Name : Opsynvi
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 03, 2023
Details:
The investigational single tablet combination therapy of ACT-064992D (macitentan) Endothelin A receptor 10mg and tadalafil PDE5 inhibitor 40mg (M/T STCT) for the long-term treatment of pulmonary arterial hypertension.
Lead Product(s): Macitentan,Tadalafil
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: ACT-064992D
Study Phase: Phase IIIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable May 30, 2023
Lead Product(s) : Macitentan,Tadalafil
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The investigational single tablet combination therapy of ACT-064992D (macitentan) Endothelin A receptor 10mg and tadalafil PDE5 inhibitor 40mg (M/T STCT) for the long-term treatment of pulmonary arterial hypertension.
Product Name : ACT-064992D
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 30, 2023
Details:
Macitentan tablets are an endothelin receptor antagonist (ERA) indicated for the treatment of pulmonary arterial hypertension (PAH, WHO Group I) to delay disease progression.
Lead Product(s): Macitentan
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Macitentan-Generic
Study Phase: Approved FDFProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 14, 2022
Lead Product(s) : Macitentan
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Alembic Gets US FDA Tentative Nod for Macitentan Tablets
Details : Macitentan tablets are an endothelin receptor antagonist (ERA) indicated for the treatment of pulmonary arterial hypertension (PAH, WHO Group I) to delay disease progression.
Product Name : Macitentan-Generic
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 14, 2022
Details:
Health Canada approved OPSYNVI® (macitentan 10mg and tadalafil 40mg) for long-term treatment of pulmonary arterial hypertension. Macitentan is antagonist/blocker of endothelin receptors on blood vessels and smooth muscle, and tadalafil is a selective inhibitor of PDE5.
Lead Product(s): Macitentan,Tadalafil
Therapeutic Area: Pulmonary/Respiratory Diseases Brand Name: Opsynvi
Study Phase: Approved FDFProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable October 15, 2021
Lead Product(s) : Macitentan,Tadalafil
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
OPSYNVI® (macitentan and tadalafil) Becomes the First and Only Health Canada-Approved Once Daily ...
Details : Health Canada approved OPSYNVI® (macitentan 10mg and tadalafil 40mg) for long-term treatment of pulmonary arterial hypertension. Macitentan is antagonist/blocker of endothelin receptors on blood vessels and smooth muscle, and tadalafil is a selective in...
Product Name : Opsynvi
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 15, 2021
Details:
While the primary endpoint was not met, exploratory analysis suggests a signal of reduced risk of disease progression of initial triple oral combination therapy vs initial double oral therapy for Pulmonary Arterial Hypertension (PAH) patients .
Lead Product(s): Selexipag,Macitentan,Tadalafil
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Uptravi
Study Phase: Phase IIIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable August 29, 2020
Lead Product(s) : Selexipag,Macitentan,Tadalafil
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
TRITON Phase 3b Study Results Presented at the European Society of Cardiology Congress
Details : While the primary endpoint was not met, exploratory analysis suggests a signal of reduced risk of disease progression of initial triple oral combination therapy vs initial double oral therapy for Pulmonary Arterial Hypertension (PAH) patients .
Product Name : Uptravi
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 29, 2020
5-(4-BROMOPHENYL)-4,6-DICHLOROPYRIMIDINE
CAS Number : 146533-41-7
End Use API : Macitentan
About The Company : Founded with a mission to transform strategic capital into specialty chemicals, Ami Group focuses on Agrochemicals, Cosmetics, and Polymers. Ami Organics Ltd. i...
5-(4-bromophenyl)-4,6-dichloropyrimidine
CAS Number : 146533-41-7
End Use API : Macitentan
About The Company : Beijing Cooperate Pharmaceutical Co.,Ltd is a high-tech company specializing in pharmaceutical and advanced material, involving API,pharmaceutical intermediates...
2-(4-Bromophenyl)-propanedioic acid, 1,3-mdiethyl ...
CAS Number : 149506-35-4
End Use API : Macitentan
About The Company : Beijing Cooperate Pharmaceutical Co.,Ltd is a high-tech company specializing in pharmaceutical and advanced material, involving API,pharmaceutical intermediates...
5-(4-Bromophenyl)pyrimidine-4,6-diol
CAS Number : 706811-25-8
End Use API : Macitentan
About The Company : Beijing Cooperate Pharmaceutical Co.,Ltd is a high-tech company specializing in pharmaceutical and advanced material, involving API,pharmaceutical intermediates...
CAS Number : 147962-41-2
End Use API : Macitentan
About The Company : Beijing Cooperate Pharmaceutical Co.,Ltd is a high-tech company specializing in pharmaceutical and advanced material, involving API,pharmaceutical intermediates...
CAS Number : 147962-41-2
End Use API : Macitentan
About The Company : Our journey began in 1969, with our first manufacturing facility Jet Chemicals Pvt. Ltd (JCPL), a pioneer in manufacturing Pharmaceutical Excipients (Saccharin ...
CAS Number : 147962-41-2
End Use API : Macitentan
About The Company : Blue Jet Healthcare is a global, science-driven pharmaceutical company specializing in collaboration, development, and manufacturing of advanced pharmaceutical ...
5-(4-Bromophenyl)-4,6-dichloropyrimidine
CAS Number : 146533-41-7
End Use API : Macitentan
About The Company : Glenfin Chemicals, a trusted provider of high-quality chemical solutions tailored to meet the diverse needs of industries worldwide. Based in the heart of inno...
5-4-bromophenyl-4,6-dichloropyrimidine
CAS Number : 146533-41-7
End Use API : Macitentan
About The Company : Established in 2011 and situated in Hangzhou, Zhejiang, China, Hangzhou Longshine Bio-Tech CO., Ltd is dedicated to providing services for pharmaceutical and ch...
N -propylsulfamide
CAS Number : 147962-41-2
End Use API : Macitentan
About The Company : Established in 2011 and situated in Hangzhou, Zhejiang, China, Hangzhou Longshine Bio-Tech CO., Ltd is dedicated to providing services for pharmaceutical and ch...
RLD : No
TE Code :
Brand Name : MACITENTAN
Dosage Form : TABLET;ORAL
Dosage Strength : 10MG
Approval Date : 2024-01-09
Application Number : 211195
RX/OTC/DISCN : DISCN
RLD : No
TE Code :
RLD : No
TE Code :
Brand Name : MACITENTAN
Dosage Form : TABLET;ORAL
Dosage Strength : 10MG
Approval Date : 2023-04-18
Application Number : 211198
RX/OTC/DISCN : DISCN
RLD : No
TE Code :
RLD : Yes
TE Code :
Brand Name : OPSUMIT
Dosage Form : TABLET;ORAL
Dosage Strength : 10MG
Approval Date : 2013-10-18
Application Number : 204410
RX/OTC/DISCN : RX
RLD : Yes
TE Code :
RLD :
TE Code :
Brand Name : MACITENTAN
Dosage Form : TABLET;ORAL
Dosage Strength : 10MG
Approval Date :
Application Number : 211136
RX/OTC/DISCN :
RLD :
TE Code :
RLD :
TE Code :
Brand Name : MACITENTAN
Dosage Form : TABLET;ORAL
Dosage Strength : 10MG
Approval Date :
Application Number : 214112
RX/OTC/DISCN :
RLD :
TE Code :
RLD :
TE Code :
Brand Name : MACITENTAN
Dosage Form : TABLET; ORAL
Dosage Strength : 10MG
Approval Date :
Application Number : 211123
RX/OTC/DISCN :
RLD :
TE Code :
RLD : No
TE Code :
Brand Name : MACITENTAN
Dosage Form : TABLET;ORAL
Dosage Strength : 10MG
Approval Date : 2024-08-05
Application Number : 211107
RX/OTC/DISCN : DISCN
RLD : No
TE Code :
RLD : No
TE Code :
Brand Name : MACITENTAN
Dosage Form : TABLET;ORAL
Dosage Strength : 10MG
Approval Date : 2021-04-06
Application Number : 211224
RX/OTC/DISCN : DISCN
RLD : No
TE Code :
Regulatory Info : EU Dossier Readiness-Q4 2023
Registration Country : Germany
Brand Name :
Dosage Form : Film Coated Tablet
Dosage Strength : 10MG
Packaging :
Approval Date :
Application Number :
Regulatory Info : EU Dossier Readiness-Q4 2023
Registration Country : Germany
Regulatory Info :
Registration Country : Sweden
Brand Name : OPSUMIT
Dosage Form : FILMDRAGERAD TABLETT
Dosage Strength : 10 MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Sweden
Regulatory Info :
Registration Country : Italy
Brand Name : Opsumit
Dosage Form : Macitentan 10Mg 30 Joined' Oral Use
Dosage Strength : 30 cpr riv 10 mg
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Italy
Regulatory Info :
Registration Country : Norway
Brand Name : Opsumit
Dosage Form : Antic-calc Tablet, Film Coated
Dosage Strength : 10 mg
Packaging : Blister
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Norway
Regulatory Info :
Registration Country : Switzerland
Brand Name : Opsumit
Dosage Form : Filmtabl
Dosage Strength : 10mg
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Switzerland
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
65
PharmaCompass offers a list of Macitentan API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Macitentan manufacturer or Macitentan supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Macitentan manufacturer or Macitentan supplier.
PharmaCompass also assists you with knowing the Macitentan API Price utilized in the formulation of products. Macitentan API Price is not always fixed or binding as the Macitentan Price is obtained through a variety of data sources. The Macitentan Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A opsumit manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of opsumit, including repackagers and relabelers. The FDA regulates opsumit manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. opsumit API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of opsumit manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A opsumit supplier is an individual or a company that provides opsumit active pharmaceutical ingredient (API) or opsumit finished formulations upon request. The opsumit suppliers may include opsumit API manufacturers, exporters, distributors and traders.
click here to find a list of opsumit suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A opsumit DMF (Drug Master File) is a document detailing the whole manufacturing process of opsumit active pharmaceutical ingredient (API) in detail. Different forms of opsumit DMFs exist exist since differing nations have different regulations, such as opsumit USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A opsumit DMF submitted to regulatory agencies in the US is known as a USDMF. opsumit USDMF includes data on opsumit's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The opsumit USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of opsumit suppliers with USDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a opsumit Drug Master File in Korea (opsumit KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of opsumit. The MFDS reviews the opsumit KDMF as part of the drug registration process and uses the information provided in the opsumit KDMF to evaluate the safety and efficacy of the drug.
After submitting a opsumit KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their opsumit API can apply through the Korea Drug Master File (KDMF).
click here to find a list of opsumit suppliers with KDMF on PharmaCompass.
A opsumit written confirmation (opsumit WC) is an official document issued by a regulatory agency to a opsumit manufacturer, verifying that the manufacturing facility of a opsumit active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting opsumit APIs or opsumit finished pharmaceutical products to another nation, regulatory agencies frequently require a opsumit WC (written confirmation) as part of the regulatory process.
click here to find a list of opsumit suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing opsumit as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for opsumit API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture opsumit as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain opsumit and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a opsumit NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of opsumit suppliers with NDC on PharmaCompass.
opsumit Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of opsumit GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right opsumit GMP manufacturer or opsumit GMP API supplier for your needs.
A opsumit CoA (Certificate of Analysis) is a formal document that attests to opsumit's compliance with opsumit specifications and serves as a tool for batch-level quality control.
opsumit CoA mostly includes findings from lab analyses of a specific batch. For each opsumit CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
opsumit may be tested according to a variety of international standards, such as European Pharmacopoeia (opsumit EP), opsumit JP (Japanese Pharmacopeia) and the US Pharmacopoeia (opsumit USP).